Impact of Early Conventional Treatment on Adult Bone and Joints in a Murine Model of X-Linked Hypophosphatemia

被引:12
|
作者
Cauliez, Axelle [1 ,2 ,3 ]
Zhukouskaya, Volha V. [1 ,2 ,3 ,4 ,5 ,6 ]
Hilliquin, Stephane [1 ,2 ,3 ,7 ]
Sadoine, Jeremy [1 ,2 ,3 ]
Slimani, Lotfi [1 ,2 ,3 ]
Miceli-Richard, Corinne [7 ]
Briot, Karine [4 ,5 ,6 ,7 ]
Linglart, Agnes [4 ,5 ,6 ,8 ]
Chaussain, Catherine [1 ,2 ,3 ,4 ,5 ,6 ,9 ]
Bardet, Claire [1 ,2 ,3 ]
机构
[1] Univ Paris, Lab Orofacial Pathol Imaging & Biotherapies URP 2, Montrouge, France
[2] Univ Paris, FHU DDS Net, Dent Sch, Montrouge, France
[3] Plateforme Imagerie Vivant PIV, Montrouge, France
[4] Univ Paris Saclay, Univ Evry, INSERM, INTEGRARE,Genethon, Evry, France
[5] Hop Bicetre, Ctr Reference Malad Rares Metabolisme Calcium & P, Plateforme Expertise Malad Rares Paris Saclay, Filiere OSCAR,EndoRare, Le Kremlin Bicetre, France
[6] Hop Bicetre, BOND ERN, Le Kremlin Bicetre, France
[7] Univ Paris, Cochin Hosp, Dept Rheumatol, Paris, France
[8] Univ Paris Saclay, Hop Bicetre, AP HP, INSERM,U1185,Serv Endocrinol & Diabete Enfant,Ser, Le Kremlin Bicetre, France
[9] Bretonneau Hosp, AP HP, Reference Ctr Rare Disorders Calcium & Phosphate, Dent Med Dept,GHN, Paris, France
来源
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2021年 / 8卷
关键词
rickets; osteomalacia; Hyp mice; phosphorus; conventional treatment; XLH; PHEX; fibroblast growth factor 23;
D O I
10.3389/fcell.2020.591417
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
X-linked hypophosphatemia (XLH) is the most common form of genetic rickets. Mainly diagnosed during childhood because of growth retardation and deformities of the lower limbs, the disease affects adults with early enthesopathies and joint structural damage that significantly alter patient quality of life. The conventional treatment, based on phosphorus supplementation and active vitamin D analogs, is commonly administered from early childhood to the end of growth; unfortunately, it does not allow complete recovery from skeletal damage. Despite adequate treatment during childhood, bone and joint complications occur in adults and become a dominant feature in the natural history of the disease. Our previous data showed that the Hyp mouse is a relevant model of XLH for studying early enthesophytes and joint structural damage. Here, we studied the effect of conventional treatment on the development of bone and joint alterations in this mouse model during growth and young adulthood. Mice were supplemented with oral phosphorus and calcitriol injections, following two timelines: (i) from weaning to 3 months of age and (ii) from 2 to 3 months to evaluate the effects of treatment on the development of early enthesophytes and joint alterations, and on changes in bone and joint deformities already present, respectively. We showed that early conventional treatment improved bone microarchitecture, and partially prevented bone and joint complications, but with no noticeable improvement in enthesophytes. In contrast, later administration had limited efficacy in ameliorating bone and joint alterations. Despite the improvement in bone microarchitecture, the conventional treatment, early or late, had no effect on osteoid accumulation. Our data underline the usefulness of the Hyp murine model for preclinical studies on skeletal and extraskeletal lesions. Although the early conventional treatment is important for the improvement of bone microarchitecture, the persistence of osteomalacia implies seeking new therapeutic strategies, in particular anti-FGF23 approach, in order to optimize the treatment of XLH.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia
    dos Santos, Elis J. Lira
    Nakajima, Kenta
    Po, Julien
    Hanai, Ayako
    Zhukouskaya, Volha
    Duplan, Martin Biosse
    Linglart, Agnes
    Shimada, Takashi
    Chaussain, Catherine
    Bardet, Claire
    INTERNATIONAL JOURNAL OF ORAL SCIENCE, 2023, 15 (01)
  • [42] Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption
    Johnson, Kristen
    Levine, Kymberly
    Sergi, Joseph
    Chamoun, Jean
    Roach, Rachel
    Vekich, Jacqueline
    Favis, Mike
    Horn, Mark
    Cao, Xianjun
    Miller, Brian
    Snyder, William
    Aivazian, Dikran
    Reagan, William
    Berryman, Edwin
    Colangelo, Jennifer
    Markiewicz, Victoria
    Bagi, Cedo M.
    Brown, Thomas P.
    Coyle, Anthony
    Mohammadi, Moosa
    Magram, Jeanne
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 (10) : 2062 - 2073
  • [43] Hormonal Regulation of Osteocyte Perilacunar and Canalicular Remodeling in the Hyp Mouse Model of X-Linked Hypophosphatemia
    Tokarz, Danielle
    Martins, Janaina S.
    Petit, Elizabeth T.
    Lin, Charles P.
    Demay, Marie B.
    Liu, Eva S.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (03) : 499 - 509
  • [44] Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia
    Martin Ramos, Silvia
    Gil-Calvo, Marta
    Roldan, Virginia
    Castellano Martinez, Ana
    Santos, Fernando
    FRONTIERS IN PEDIATRICS, 2020, 8
  • [45] Genetic analysis combined with 3D-printing assistant surgery in diagnosis and treatment for an X-linked hypophosphatemia patient
    Jin, Jie-Yuan
    Zhang, Li-Yang
    Guo, Shuai
    Tang, Ke
    Zeng, Lei
    Xiang, Rong
    Liang, Jie-Yu
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (03)
  • [46] Lumbar and radial bone mineral density in children and adolescents with X-linked hypophosphatemia: evaluation with dual X-ray absorptiometry
    Shore, RM
    Langman, CB
    Poznanski, AK
    SKELETAL RADIOLOGY, 2000, 29 (02) : 90 - 93
  • [47] Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review
    Jurca, Claudia Maria
    Iuhas, Oana
    Kozma, Kinga
    Petchesi, Codruta Diana
    Zaha, Dana Carmen
    Bembea, Marius
    Jurca, Sanziana
    Paul, Corina
    Jurca, Alexandru Daniel
    GENES, 2022, 13 (08)
  • [48] Lumbar and radial bone mineral density in children and adolescents with X-linked hypophosphatemia: evaluation with dual X-ray absorptiometry
    R. M. Shore
    C. B. Langman
    A. K. Poznanski
    Skeletal Radiology, 2000, 29 : 90 - 93
  • [49] Bone Matrix Mineralization and Response to Burosumab in Adult Patients With X-Linked Hypophosphatemia: Results From the Phase 3, Single-Arm International Trial
    Fratzl-Zelman, Nadja
    Hartmann, Markus A.
    Gamsjaeger, Sonja
    Rokidi, Stamatia
    Paschalis, Eleftherios P.
    Blouin, Stephane
    Zwerina, Jochen
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 (09) : 1665 - 1678
  • [50] Presentation and non-surgical endodontic treatment of two patients with X-linked hypophosphatemia: a case report
    Bradley, H.
    Dutta, A.
    Philpott, R.
    INTERNATIONAL ENDODONTIC JOURNAL, 2021, 54 (08) : 1403 - 1414